Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2021-05-13 Purchase | 2021-05-17 07:02 am | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 5,925,925 | $1.35 | $7,999,999 | 7,804,778 (Indirect) | View |
| 2020-11-17 Purchase | 2020-11-19 4:40 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner | 60,000 | $50 | $3,000,000 | 155,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:16 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2019-06-27 Purchase | 2019-07-01 11:50 am | ARQULE INC | ARQL | Nussbaum Ran Director | 307,692 | $9.75 | $2,999,997 | 45,534 (Indirect) | View |
| 2019-06-24 Purchase | 2019-06-26 4:51 pm | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 200,000 | $9 | $1,800,000 | 7,212,186 (Indirect) | View |
| 2018-07-13 Purchase | 2018-10-22 2:54 pm | ARQULE INC | ARQL | Nussbaum Ran Director | 181,818 | $5.5 | $999,999 | 1,639,268 (Indirect) | View |
| 2018-05-18 Purchase(A) | 2018-05-22 09:22 am | ARQULE INC | ARQL | Nussbaum Ran Director | 8,611 | $3.29 | $28,330 | 6,616,611 (Indirect) | View |
| 2018-05-18 Purchase | 2018-05-18 5:41 pm | ARQULE INC | ARQL | Nussbaum Ran Director | 8,611 | $3.29 | $28,330 | 8,611 (Direct) | View |
| 2018-04-30 Purchase | 2018-05-01 4:34 pm | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 350,000 | $9.75 | $3,412,500 | 7,708,582 (Indirect) | View |
| 2018-03-21 Purchase | 2018-03-23 4:20 pm | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 12,600 | $7.7643 | $97,830 | 7,615,249 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
| 2020-04-07(A) Ownership | 2022-11-30 4:36 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 0 | $0 | 7,176 (Indirect) | View |
| 2022-10-21 Exercise | 2022-10-25 4:57 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $5.94 | 1,481,927 (Indirect) | View |
| 2022-10-21 Exercise | 2022-10-25 4:57 pm | 2018-12-27 2022-12-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $0 | 1,481,927 (Indirect) | View |
| 2022-06-06 Exercise | 2022-08-25 3:25 pm | 2015-09-01 2022-08-31 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,433,928 (Indirect) | View |
| 2022-06-06 Exercise | 2022-08-25 3:25 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,433,928 (Indirect) | View |
| 2022-06-15 Option Award | 2022-06-17 08:26 am | N/A 2032-06-15 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 3:36 pm | N/A 2032-06-08 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 10,000 (Indirect) | View |
| 2022-06-01 Option Award | 2022-06-03 4:30 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 8,293 | $0 | 8,293 (Direct) | View |
| 2021-03-25(A) Exercise | 2021-06-09 1:46 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,431,717 (Indirect) | View |
| 2021-03-25(A) Exercise | 2021-06-09 1:46 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,431,717 (Indirect) | View |
| 2021-03-25 Option Award | 2021-06-09 1:42 pm | N/A 2031-06-06 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 1,443,928 (Indirect) | View |
| 2021-03-25 Exercise | 2021-06-09 1:42 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $0 | 1,443,928 (Indirect) | View |
| 2021-03-25 Exercise | 2021-06-09 1:42 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $5 | 1,443,928 (Indirect) | View |
| 2021-06-01 Option Award | 2021-06-03 5:34 pm | N/A 2031-05-31 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 8,293 | $0 | 8,293 (Direct) | View |
| 2021-05-19 Option Award | 2021-05-20 4:10 pm | N/A 2031-05-19 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2021-03-24 Exercise | 2021-04-22 5:18 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,465,199 (Indirect) | View |
| 2021-03-24 Exercise | 2021-04-22 5:18 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,465,199 (Indirect) | View |
| 2021-01-22 Equity Swap | 2021-01-26 5:07 pm | N/A N/A | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 1,576,881 | $0 | 0 (Indirect) | View |
| 2021-01-22 Disposition | 2021-01-26 5:07 pm | N/A N/A | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 17,000 | $0 | 0 (Direct) | View |
| 2020-06-17 Option Award | 2020-06-19 6:38 pm | N/A 2030-06-17 | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 17,000 | $0 | 17,000 (Direct) | View |
| 2020-06-08 Option Award | 2020-06-10 6:41 pm | N/A 2030-06-07 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2020-05-20 Option Award | 2020-05-22 4:10 pm | N/A 2030-05-20 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 3,545,100 | $0 | 149,262 (Indirect) | View |
| 2020-04-07 Ownership | 2020-04-07 7:34 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 0 | $0 | 4,297,008 (Indirect) | View |
| 2020-01-16 Disposition | 2020-01-16 3:57 pm | N/A 2027-11-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 90,000 | $0 | 0 (Direct) | View |
| 2020-01-16 Equity Swap | 2020-01-16 3:57 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 8,744,820 | $20 | 0 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 1,669,714 | $0 | 2,134,350 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 1,669,714 | $1.75 | 2,134,350 (Indirect) | View |
| 2019-12-24 Tax Withholding | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 145,301 | $20.11 | 2,134,350 (Indirect) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A 2021-10-20 | ARQULE INC | ARQL | Nussbaum Ran Director | 114,286 | $0 | 3,438,363 (Indirect) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 114,286 | $1.75 | 3,438,363 (Indirect) | View |
| 2019-06-19 Ownership | 2019-06-19 6:33 pm | N/A N/A | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 0 | $0 | 1,576,881 (Indirect) | View |
| 2019-06-03 Option Award | 2019-06-05 4:55 pm | N/A 2029-06-02 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2019-05-29(A) Option Award | 2019-05-30 3:45 pm | N/A 2029-05-29 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2019-05-29 Option Award | 2019-05-29 5:21 pm | N/A 2029-05-29 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2019-05-14 Option Award | 2019-05-15 12:44 pm | N/A 2029-05-13 | ARQULE INC | ARQL | Nussbaum Ran Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2019-01-01 Ownership | 2019-01-10 5:16 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 0 | $0 | 1,485,168 (Indirect) | View |
| 2018-06-15 Option Award | 2018-06-19 6:17 pm | N/A 2028-06-15 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2018-05-08 Other | 2018-05-25 4:30 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 8,392,000 | $0 | 9,979,000 (Indirect) | View |
| 2018-05-08 Option Award | 2018-05-10 12:45 pm | N/A 2028-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |